BlackRock’s Opus Genetics IRD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $12.8M | Buy |
3,116,487
+2,968,747
| +2,009% | +$13.8M | ﹤0.01% | 3541 |
|
|
2026
Q1 | $672K | Buy |
147,740
+5,843
| +4% | +$20.2K | ﹤0.01% | 4454 |
|
|
2025
Q4 | $285K | Buy |
141,897
+95,803
| +208% | +$194K | ﹤0.01% | 4625 |
|
|
2025
Q3 | $76.1K | Hold |
46,094
| – | – | ﹤0.01% | 4900 |
|
|
2025
Q2 | $43.4K | Sell |
46,094
-62,433
| -58% | -$57.8K | ﹤0.01% | 5016 |
|
|
2025
Q1 | $107K | Sell |
108,527
-1,194
| -1% | -$1.33K | ﹤0.01% | 4754 |
|
|
2024
Q4 | $131K | Buy |
109,721
+398
| +0.4% | +$457 | ﹤0.01% | 4720 |
|
|
2024
Q3 | $143K | Buy |
109,323
+2,388
| +2% | +$3.68K | ﹤0.01% | 4600 |
|
|
2024
Q2 | $164K | Buy |
106,935
+10,221
| +11% | +$17.7K | ﹤0.01% | 4588 |
|
|
2024
Q1 | $194K | Buy |
96,714
+2,393
| +3% | +$6.07K | ﹤0.01% | 4587 |
|
|
2023
Q4 | $284K | Buy |
94,321
+1,036
| +1% | +$3.06K | ﹤0.01% | 4556 |
|
|
2023
Q3 | $313K | Buy |
93,285
+37,886
| +68% | +$152K | ﹤0.01% | 4555 |
|
|
2023
Q2 | $240K | Buy |
55,399
+3,198
| +6% | +$15.2K | ﹤0.01% | 4683 |
|
|
2023
Q1 | $196K | Sell |
52,201
-19,501
| -27% | -$70K | ﹤0.01% | 4781 |
|
|
2022
Q4 | $253K | Buy |
71,702
+4,985
| +7% | +$13.1K | ﹤0.01% | 4789 |
|
|
2022
Q3 | $135K | Sell |
66,717
-4,452
| -6% | -$9.6K | ﹤0.01% | 5086 |
|
|
2022
Q2 | $136K | Buy |
71,169
+36,903
| +108% | +$83.9K | ﹤0.01% | 5145 |
|
|
2022
Q1 | $112K | Sell |
34,266
-1,341
| -4% | -$4.59K | ﹤0.01% | 5263 |
|
|
2021
Q4 | $133K | Buy |
35,607
+1,694
| +5% | +$6.79K | ﹤0.01% | 5197 |
|
|
2021
Q3 | $175K | Sell |
33,913
-514
| -1% | -$2.37K | ﹤0.01% | 5016 |
|
|
2021
Q2 | $181K | Buy |
34,427
+32,220
| +1,460% | +$160K | ﹤0.01% | 4914 |
|
|
2021
Q1 | $13K | Hold |
2,207
| – | – | ﹤0.01% | 5067 |
|
|
2020
Q4 | $15K | Sell |
2,207
-1
| -0% | -$7 | ﹤0.01% | 4811 |
|
|
2020
Q3 | $18K | Hold |
2,208
| – | – | ﹤0.01% | 4738 |
|
|
2020
Q2 | $25K | Hold |
2,208
| – | – | ﹤0.01% | 4666 |
|
|
2020
Q1 | $16K | Hold |
2,208
| – | – | ﹤0.01% | 4651 |
|
|
2019
Q4 | $17K | Hold |
2,208
| – | – | ﹤0.01% | 4686 |
|
|
2019
Q3 | $18K | Hold |
2,208
| – | – | ﹤0.01% | 4658 |
|
|
2019
Q2 | $45K | Sell |
2,208
-2,638
| -54% | -$59.6K | ﹤0.01% | 4591 |
|
|
2019
Q1 | $119K | Buy |
4,846
+509
| +12% | +$16.9K | ﹤0.01% | 4352 |
|
|
2018
Q4 | $194K | Buy |
4,337
+318
| +8% | +$18.6K | ﹤0.01% | 4237 |
|
|
2018
Q3 | $344K | Buy |
4,019
+82
| +2% | +$6.33K | ﹤0.01% | 4206 |
|
|
2018
Q2 | $266K | Buy |
3,937
+241
| +7% | +$21.2K | ﹤0.01% | 4249 |
|
|
2018
Q1 | $268K | Buy |
3,696
+18
| +0.5% | +$1.64K | ﹤0.01% | 4151 |
|
|
2017
Q4 | $356K | Buy |
3,678
+90
| +3% | +$9.14K | ﹤0.01% | 4106 |
|
|
2017
Q3 | $417K | Buy |
3,588
+121
| +3% | +$13K | ﹤0.01% | 4090 |
|
|
2017
Q2 | $475K | Buy |
3,467
+2,534
| +272% | +$493K | ﹤0.01% | 4036 |
|
|
2017
Q1 | $229K | Buy |
+933
| New | +$121K | ﹤0.01% | 4189 |
|
|
2014
Q2 | – | Hold |
0
| – | – | – | 3231 |
|
|
2014
Q1 | – | Hold |
0
| – | – | – | 3172 |
|
Other funds holding IRD
CP
BCM
NCM
BCM
TECP
GPP
BlackRock's IRD Position: Q2 2026 in Review
BlackRock increased its Opus Genetics (IRD) stake by 2,009% in Q2 2026, buying an estimated $13.8M and bringing the position to 3,116,487 shares worth $12.8M. The position accounts for ﹤0.01% of the portfolio, ranked #3541.
BlackRock first reported a position in IRD in Q1 2017 and has held it in 38 quarters since. 103 funds tracked by Wall St. Rank hold IRD as of Q2 2026.
- BlackRock held 3,116,487 shares of Opus Genetics worth $12.8M as of Q2 2026.
- BlackRock bought 2,968,747 Opus Genetics shares in Q2 2026, an estimated $13.8M.
- Opus Genetics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3541 holding.
- BlackRock first reported a position in Opus Genetics in Q1 2017 and has held it in 38 quarters since.
- 103 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.